Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study

BACKGROUND: Spiromax® is a novel dry-powder inhaler containing formulations of budesonide plus formoterol (BF). The device is intended to provide dose equivalence with enhanced user-friendliness compared to BF Turbuhaler® in asthma and chronic obstructive pulmonary disease (COPD). The present study...

Descripción completa

Detalles Bibliográficos
Autores principales: Azouz, Wahida, Chetcuti, Philip, Hosker, Harold, Saralaya, Dinesh, Chrystyn, Henry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450517/
https://www.ncbi.nlm.nih.gov/pubmed/25927483
http://dx.doi.org/10.1186/s12890-015-0043-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450517/
https://www.ncbi.nlm.nih.gov/pubmed/25927483
http://dx.doi.org/10.1186/s12890-015-0043-x

Ejemplares similares